Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01029782
Other study ID # KGHQEII-0001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2010
Est. completion date October 2014

Study information

Verified date August 2018
Source Kelowna General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether oral cephalexin is equivalent to intravenous cefazolin plus oral probenecid for the treatment of uncomplicated skin and soft tissue infections in patients that present to the emergency department.


Description:

Skin and soft tissue infections (SSTIs) are a common reason for presentation to an Emergency Department (ED) in Canada. Although many patients with mild SSTI are able to be managed at home with oral antibiotics, those with mild-moderate infections are often treated with parenteral antibiotics. Current practice patterns in Canadian EDs indicate this patient population is often treated with intravenous cefazolin once daily along with oral probenecid and return to the ED or other ambulatory setting for daily medication administration and assessment. This parenteral regimen has been found to result in success rates comparable to studies which have evaluated treatment success with oral antibiotics in this patient population (89-97%). Although successful outcome can be achieved with this approach, it is often inconvenient for the patient to return to the ED/ambulatory care unit daily and does contribute to overall ED/ambulatory care visit volumes and overall health care costs. Unfortunately, there has never been a study which has evaluated the relative efficacy and safety or oral antibiotics to the aforementioned parenteral approach in this patient population and thus there remains a significant knowledge gap which must be addressed before a change in current practice can be explored.

The objective of the study is to determine whether oral cephalexin is equivalent to intravenous cefazolin plus oral probenecid for the treatment of uncomplicated SSTIs in patients that present to the ED. This study will be a prospective, multi-centered, randomized controlled non-inferiority trial comparing cephalexin 500 mg orally four times to cefazolin 2 g IV plus probenecid 1 g orally, in patients presenting to the ED with presumed diagnosis of SSTI. The primary outcome will be to compare the proportion of patients failing therapy for their cellulitis after 72 hours of antibiotic treatment with oral cephalexin or IV cefazolin/oral probenecid 1 g daily. Secondary outcomes include the clinical cure rate at 7 days, percentage of patients requiring hospital admission, percentage of patients stepped down to oral antibiotics on or before day 7 of therapy, percentage of patients requiring an additional antibiotic prescription on day 7, and the frequency of adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 206
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Patients presenting to the emergency department with a presumed diagnosis of mild to moderate skin and soft tissue infection

- Deemed well enough to be treated as an outpatient

- 19 years of age or older

Exclusion Criteria:

- known allergy to study drugs

- known chronic kidney disease with a creatinine clearance <30 mL/min

- known previous methicillin-resistant staphylococcus aureus (MRSA) infection

- use of antibiotics for greater than 24 hours in the past 7 days

- wound/abscess requiring operative debridement or incision and drainage

- suspected necrotizing fasciitis, osteomyelitis or septic arthritis

- febrile neutropenia

- concomitant documented bacteremia

- Two or more signs of systemic sepsis

- new altered mental status

- infections at a site involving prosthetic materials

- animal or human bite wound infections

- post-operative wound infections

- known peripheral vascular disease

- superficial thrombophlebitis

- pregnant/breastfeeding

- obesity (BMI > 30 kg/m2)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IV cefazolin plus oral probenecid and placebo cephalexin
Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
Oral cephalexin and saline IV plus probenecid placebo
Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily

Locations

Country Name City State
Canada Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia
Canada Kelowna General Hospital Kelowna British Columbia

Sponsors (4)

Lead Sponsor Collaborator
Kelowna General Hospital Canadian Society of Hospital Pharmacists, Capital Health, Canada, Interior Health Authority, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid. 72 hours
See also
  Status Clinical Trial Phase
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Not yet recruiting NCT01947660 - Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery N/A
Completed NCT01876628 - Adjunctive Clindamycin for Cellulitis: C4C Trial. Phase 4
Active, not recruiting NCT01706913 - Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis N/A
Completed NCT03474523 - Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment N/A
Recruiting NCT03312946 - Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite. N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Active, not recruiting NCT03785834 - The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis
Completed NCT01549613 - Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections Phase 4
Completed NCT00676130 - Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients N/A
Not yet recruiting NCT03917134 - Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy N/A
Completed NCT02230813 - Predictors of Oral Antibiotic Treatment Failure in Emergency Department Patients With Cellulitis N/A
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Completed NCT01339091 - Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT00984022 - Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage Phase 2
Completed NCT04091672 - RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction N/A
Completed NCT05023200 - The Personalised Antibiotic Duration for Cellulitis (PAD-C) Study
Terminated NCT02087527 - Use of Corticosteroids in Children With Cellulitis N/A